2US0 Stock Chart & Stats
€4.73
--
Market closed
€4.73
--
Day’s Range― - ―
52-Week Range€4.54 - €4.73
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€15.72M
Enterprise Value€31.14
Total Cash (Recent Filing)€29.74M
Total Debt (Recent Filing)€4.92M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Jul 30, 2026EPS Estimate
-1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.07
Shares Outstanding4,068,951
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.54Price Target Upside270.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNextCure's modest debt load materially reduces near-term refinancing and solvency risk versus peers reliant on high leverage. For a cash-burning clinical-stage biotech, low leverage preserves optionality for strategic financing or partnerships and limits fixed interest obligations over the next several quarters.
Positive Clinical Signal (SIM0505)A 55% ORR in Phase 1 dose-escalation (including ovarian and uterine serous carcinoma) is a meaningful de-risking milestone for an ADC program. Durable clinical signals can unlock partnerships, non-dilutive deals, or sponsor-led late-stage investment, and materially improve long-term commercial and licensing prospects if replicated in later trials.
Material Strategic Financing & Merger BackingThe announced all-stock merger with Avere plus a $320M concurrent financing materially bolsters funding for the combined company's lead oral IL-23 program through Phase 3 milestones. Structural funding and an experienced management team improve execution capacity for late-stage development and reduce immediate cash-runway pressure.
Bears Say
Sustained Cash Burn & LossesNextCure reports no product revenue and persistent large operating losses and negative free cash flow, requiring continual external financing. Over the medium term, sustained cash burn elevates dilution risk, constrains R&D flexibility, and makes long-term viability dependent on successful clinical outcomes or significant partner funding.
Severe Shareholder Dilution From MergerThe merger terms transfer near-total ownership to Avere holders and PIPE investors, leaving legacy shareholders with a ~1–2% stake plus contingent value rights. This structural dilution substantially limits upside capture for existing investors and changes incentive alignment, reducing the benefit of future upside tied to the combined entity.
No Commercial Products; Funding DependenceAs a clinical-stage biotech without commercial products, NextCure depends on capital markets, milestone payments, or licensing for operations. That structural dependence makes the company sensitive to financing availability and partner terms, increasing execution and timing risk across the 2–6 month horizon absent definitive non-dilutive deals.
NextCure News
2US0 FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was €4.54 and its highest was €4.73 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is €15.72M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Jul 30, 2026 which is in 5 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Apr 30, 2026. The company reported -€1.642 earnings per share for the quarter, beating the consensus estimate of -€1.849 by €0.206.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.71.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,068,951 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -€1.642 in its last earnings report, beating expectations of -€1.849. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in DE:2US0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
2US0 Stock 12 Month Forecast
Average Price Target
€17.54
▲(270.85% Upside)